Evidence map›Paper›PMID 33398532›Full record

Trial reportJournal of neuro-oncology2021

A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.

Alipi V Bonm, Alec W Gibson, Leona A Holmberg, Marco Mielcarek, Tresa McGranahan, Lynne P Taylor, Jerome J Graber

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alipi V BonmDepartment of Neurology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0340-2008
Alec W GibsonMedical Scientist Training Program, University of Washington, Seattle, WA, USA.
Leona A HolmbergDepartment of Medicine, University of Washington, Seattle, WA, USA.
Marco MielcarekDepartment of Medicine, University of Washington, Seattle, WA, USA.
Tresa McGranahanDepartments of Neurology and Neurosurgery, Alvord Brain Tumor Center, University of Washington Medical Center, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Lynne P TaylorDepartments of Neurology and Neurosurgery, Alvord Brain Tumor Center, University of Washington Medical Center, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Jerome J GraberDepartments of Neurology and Neurosurgery, Alvord Brain Tumor Center, University of Washington Medical Center, 1959 NE Pacific St, Seattle, WA, 98195, USA. jgraber@uw.edu.
University of Washington · USUniversity of Washington Medical Center · US

Funding

Neurosurgery research training in interdisciplinary neuroscienceR25NS079200 · NINDS · UNIVERSITY OF WASHINGTON · PI OJEMANN, JEFFREY G · 2012 to 2021
$1.2M
NINDS NIH HHS NS079200NINDS NIH HHS R25 NS079200
6 · The paper itself

Abstract

backgroundRelapsed or refractory primary CNS lymphoma (rrPCNSL) is a rare and challenging malignancy for which better evidence is needed to guide management.

methodsWe present a retrospective cohort of 66 consecutive patients with rrPCNSL treated at the University of Washington between 2000 and 2020. Immunosuppressed and secondary CNS lymphoma patients were excluded.

resultsDuring a median follow-up of 40.5 months from initial diagnosis, median OS for relapsed disease was 14.1 (0.2-88.5) months and median PFS was 11.0 (0.2-73.9) months. At diagnosis (r

conclusionsPFS may be a useful surrogate endpoint which predicts OS in PCNSL. Consolidation with ASCT was associated with improved PFS in rrPCNSL.

Indexed as

Salvage TherapyAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCombined Modality TherapyConsolidation ChemotherapyDrug Resistance, NeoplasmFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphomaMaleMiddle AgedAutologous peripheral blood stem cell transplantPrimary CNS lymphomaProgression-free survivalRecurrent primary CNS lymphomaSurrogate endpoints

Identifiers

PMID33398532
OpenAlexW3119108778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.